Scientists probe GLP-1's role in Post-Bypass blood sugar woes
NCT ID NCT01803451
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study looks at how a hormone called GLP-1 helps control blood sugar and weight loss after gastric bypass surgery. Researchers will give a drug that blocks GLP-1 to 80 people, including those who had surgery and healthy controls, to measure its effects. The goal is to understand why some patients develop low blood sugar after surgery and how GLP-1 contributes to improved glucose metabolism.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- exendin-(9-39)
- What this could lead to
- If successful, this could clarify why some patients develop low blood sugar after gastric bypass and point toward better management strategies.
- What could go wrong
- This is an early-phase, observational study with only 80 participants. It is not testing a new treatment, so direct patient benefits are uncertain.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for POST-BARIATRIC SURGERY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
South Texas Veterans Health Care System
RECRUITINGSan Antonio, Texas, 78229, United States
-
Texas Diabetes Institute - University Health System
RECRUITINGSan Antonio, Texas, 78207, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.